STOCK TITAN

[SCHEDULE 13G/A] Tango Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Farallon-affiliated funds and related individuals filed an amended Schedule 13G reporting material passive holdings of Tango Therapeutics common stock. Farallon Partners, L.L.C. is shown as beneficial owner of 8,798,334 shares (8.1%) and the Farallon Individual Reporting Persons are shown with a collective 9,157,000 shares (8.4%). Several underlying Farallon funds report individual holdings, including Farallon Capital Offshore Investors II with 3,754,671 shares (3.5%) and Farallon Capital Institutional Partners with 2,023,027 shares (1.9%).

The filing states the shares are held directly by the named funds and that the general partner entities and listed individuals could be deemed beneficial owners while disavowing beneficial ownership of those shares. The Schedule is a passive disclosure of ownership and includes a certification that the securities were not acquired to effect a change of control.

Fondi affiliati a Farallon e persone correlate hanno presentato un emendamento al Schedule 13G, segnalando partecipazioni passive rilevanti nelle azioni ordinarie di Tango Therapeutics. Farallon Partners, L.L.C. risulta proprietario beneficiario di 8.798.334 azioni (8,1%) e le persone di reporting individuali di Farallon risultano complessivamente titolari di 9.157.000 azioni (8,4%). Diversi fondi sottostanti di Farallon dichiarano posizioni autonome, tra cui Farallon Capital Offshore Investors II con 3.754.671 azioni (3,5%) e Farallon Capital Institutional Partners con 2.023.027 azioni (1,9%).

La documentazione indica che le azioni sono detenute direttamente dai fondi citati e che le entità general partner e le persone elencate potrebbero essere considerate beneficiarie, pur negando la proprietà beneficiaria di tali titoli. Il Schedule costituisce una comunicazione di possesso a carattere passivo e include una certificazione che i titoli non sono stati acquisiti al fine di determinare un cambiamento di controllo.

Fondos vinculados a Farallon y personas relacionadas presentaron una enmienda al Schedule 13G informando de participaciones pasivas significativas en acciones ordinarias de Tango Therapeutics. Farallon Partners, L.L.C. figura como titular beneficiario de 8.798.334 acciones (8,1%) y las Personas Informantes Individuales de Farallon aparecen con un total conjunto de 9.157.000 acciones (8,4%). Varios fondos subyacentes de Farallon declaran posiciones individuales, entre ellos Farallon Capital Offshore Investors II con 3.754.671 acciones (3,5%) y Farallon Capital Institutional Partners con 2.023.027 acciones (1,9%).

La presentación señala que las acciones están en manos directas de los fondos nombrados y que las entidades general partner y las personas listadas podrían considerarse propietarios beneficiarios, aunque niegan la condición de beneficiario de esas acciones. El Schedule es una divulgación pasiva de propiedad e incluye una certificación de que los valores no se adquirieron con el propósito de provocar un cambio de control.

Farallon 계열 펀드 및 관련 개인들이 수정된 Schedule 13G를 제출하여 Tango Therapeutics 보통주의 중요한 수동 보유를 신고했습니다. Farallon Partners, L.L.C.8,798,334주(8.1%)의 실질적 소유자로 기재되어 있으며, Farallon의 개별 보고자들은 합산하여 9,157,000주(8.4%)를 보유한 것으로 나타납니다. 여러 기초 Farallon 펀드가 개별 보유를 보고했는데, 그중 Farallon Capital Offshore Investors II3,754,671주(3.5%), Farallon Capital Institutional Partners2,023,027주(1.9%)를 보고했습니다.

신고서에는 해당 주식이 명시된 펀드에 의해 직접 보유되고 있으며, 일반 파트너 법인 및 기재된 개인들이 실질적 소유자로 간주될 수 있으나 그러한 실질 소유를 부인한다고 명시되어 있습니다. 이 Schedule은 수동적 소유 공시이며, 해당 증권이 지배권 변경을 목적으로 취득되지 않았음을 인증하는 문구를 포함하고 있습니다.

Des fonds affiliés à Farallon et des personnes liées ont déposé un Schedule 13G modifié, déclarant des participations passives significatives dans les actions ordinaires de Tango Therapeutics. Farallon Partners, L.L.C. est indiqué comme détenteur bénéficiaire de 8 798 334 actions (8,1 %) et les personnes individuelles rapportant pour Farallon détiennent collectivement 9 157 000 actions (8,4 %). Plusieurs fonds Farallon sous-jacents déclarent des positions individuelles, notamment Farallon Capital Offshore Investors II avec 3 754 671 actions (3,5 %) et Farallon Capital Institutional Partners avec 2 023 027 actions (1,9 %).

Le dépôt précise que les actions sont détenues directement par les fonds nommés et que les entités general partner ainsi que les personnes listées pourraient être considérées comme détenteurs bénéficiaires, tout en déniant la qualité de bénéficiaire pour ces actions. Le Schedule constitue une divulgation passive de détention et comporte une certification indiquant que les titres n’ont pas été acquis en vue d’un changement de contrôle.

An Farallon angeschlossene Fonds und zugehörige Personen haben ein geändertes Schedule 13G eingereicht und dabei wesentliche passive Bestände an Stammaktien von Tango Therapeutics gemeldet. Farallon Partners, L.L.C. wird als wirtschaftlicher Eigentümer von 8.798.334 Aktien (8,1%) ausgewiesen, und die einzelnen berichtspflichtigen Personen von Farallon werden zusammen mit 9.157.000 Aktien (8,4%) angegeben. Mehrere zugrundeliegende Farallon-Fonds melden einzelne Bestände, darunter Farallon Capital Offshore Investors II mit 3.754.671 Aktien (3,5%) und Farallon Capital Institutional Partners mit 2.023.027 Aktien (1,9%).

Die Einreichung gibt an, dass die Aktien unmittelbar von den genannten Fonds gehalten werden und dass die General-Partner-Einheiten sowie die aufgeführten Personen als wirtschaftliche Eigentümer angesehen werden könnten, obwohl sie die wirtschaftliche Eigentümerschaft dieser Aktien zurückweisen. Das Schedule ist eine passive Offenlegung der Beteiligung und enthält eine Bestätigung, dass die Wertpapiere nicht zum Zweck einer Kontrolländerung erworben wurden.

Positive
  • Material institutional ownership disclosed: Farallon entities report substantial positions, including 8.1% (Farallon Partners) and 8.4% (aggregate individuals).
  • Passive disclosure and certification: The filing is a Schedule 13G/A and includes a certification that the securities were not acquired to effect a change of control.
Negative
  • No sole voting or dispositive power reported for any reporting person; all reported power is shared (sole power rows show 0).
  • Group status ambiguous: the Reporting Persons state they "neither disclaim nor affirm" the existence of a group, leaving potential coordination unclear.

Insights

TL;DR Farallon entities report an >8% stake in TNGX, a material institutional holding but disclosed as passive.

This Schedule 13G/A shows concentrated institutional exposure by Farallon-related funds and named principals to Tango Therapeutics common stock. Key figures are 8.1% (Farallon Partners, L.L.C.) and 8.4% (aggregate reported by the Individual Reporting Persons). The positions are reported as shared voting and dispositive power with no sole voting or sole dispositive power indicated for any reporting person. The filing also disclaims affirmative statements about a group while acknowledging potential deemed beneficial ownership through governance roles. For investors, this is material ownership information but presented as passive.

TL;DR Material institutional ownership disclosed with disclaimers about group status and beneficial ownership—governance implications possible but not asserted.

The filing identifies multiple Farallon funds and affiliated entities as holders of Tango common stock, and names 17 individual reporting persons tied to the Farallon General Partner. The document explicitly states that the General Partner and the named individuals "may be deemed" beneficial owners while simultaneously disclaiming beneficial ownership of the reported shares. The filers also note the holdings were not acquired to change control. The combination of concentrated holdings and the group-disclaimer language is a governance item investors may track, though the filing itself presents the position as passive.

Fondi affiliati a Farallon e persone correlate hanno presentato un emendamento al Schedule 13G, segnalando partecipazioni passive rilevanti nelle azioni ordinarie di Tango Therapeutics. Farallon Partners, L.L.C. risulta proprietario beneficiario di 8.798.334 azioni (8,1%) e le persone di reporting individuali di Farallon risultano complessivamente titolari di 9.157.000 azioni (8,4%). Diversi fondi sottostanti di Farallon dichiarano posizioni autonome, tra cui Farallon Capital Offshore Investors II con 3.754.671 azioni (3,5%) e Farallon Capital Institutional Partners con 2.023.027 azioni (1,9%).

La documentazione indica che le azioni sono detenute direttamente dai fondi citati e che le entità general partner e le persone elencate potrebbero essere considerate beneficiarie, pur negando la proprietà beneficiaria di tali titoli. Il Schedule costituisce una comunicazione di possesso a carattere passivo e include una certificazione che i titoli non sono stati acquisiti al fine di determinare un cambiamento di controllo.

Fondos vinculados a Farallon y personas relacionadas presentaron una enmienda al Schedule 13G informando de participaciones pasivas significativas en acciones ordinarias de Tango Therapeutics. Farallon Partners, L.L.C. figura como titular beneficiario de 8.798.334 acciones (8,1%) y las Personas Informantes Individuales de Farallon aparecen con un total conjunto de 9.157.000 acciones (8,4%). Varios fondos subyacentes de Farallon declaran posiciones individuales, entre ellos Farallon Capital Offshore Investors II con 3.754.671 acciones (3,5%) y Farallon Capital Institutional Partners con 2.023.027 acciones (1,9%).

La presentación señala que las acciones están en manos directas de los fondos nombrados y que las entidades general partner y las personas listadas podrían considerarse propietarios beneficiarios, aunque niegan la condición de beneficiario de esas acciones. El Schedule es una divulgación pasiva de propiedad e incluye una certificación de que los valores no se adquirieron con el propósito de provocar un cambio de control.

Farallon 계열 펀드 및 관련 개인들이 수정된 Schedule 13G를 제출하여 Tango Therapeutics 보통주의 중요한 수동 보유를 신고했습니다. Farallon Partners, L.L.C.8,798,334주(8.1%)의 실질적 소유자로 기재되어 있으며, Farallon의 개별 보고자들은 합산하여 9,157,000주(8.4%)를 보유한 것으로 나타납니다. 여러 기초 Farallon 펀드가 개별 보유를 보고했는데, 그중 Farallon Capital Offshore Investors II3,754,671주(3.5%), Farallon Capital Institutional Partners2,023,027주(1.9%)를 보고했습니다.

신고서에는 해당 주식이 명시된 펀드에 의해 직접 보유되고 있으며, 일반 파트너 법인 및 기재된 개인들이 실질적 소유자로 간주될 수 있으나 그러한 실질 소유를 부인한다고 명시되어 있습니다. 이 Schedule은 수동적 소유 공시이며, 해당 증권이 지배권 변경을 목적으로 취득되지 않았음을 인증하는 문구를 포함하고 있습니다.

Des fonds affiliés à Farallon et des personnes liées ont déposé un Schedule 13G modifié, déclarant des participations passives significatives dans les actions ordinaires de Tango Therapeutics. Farallon Partners, L.L.C. est indiqué comme détenteur bénéficiaire de 8 798 334 actions (8,1 %) et les personnes individuelles rapportant pour Farallon détiennent collectivement 9 157 000 actions (8,4 %). Plusieurs fonds Farallon sous-jacents déclarent des positions individuelles, notamment Farallon Capital Offshore Investors II avec 3 754 671 actions (3,5 %) et Farallon Capital Institutional Partners avec 2 023 027 actions (1,9 %).

Le dépôt précise que les actions sont détenues directement par les fonds nommés et que les entités general partner ainsi que les personnes listées pourraient être considérées comme détenteurs bénéficiaires, tout en déniant la qualité de bénéficiaire pour ces actions. Le Schedule constitue une divulgation passive de détention et comporte une certification indiquant que les titres n’ont pas été acquis en vue d’un changement de contrôle.

An Farallon angeschlossene Fonds und zugehörige Personen haben ein geändertes Schedule 13G eingereicht und dabei wesentliche passive Bestände an Stammaktien von Tango Therapeutics gemeldet. Farallon Partners, L.L.C. wird als wirtschaftlicher Eigentümer von 8.798.334 Aktien (8,1%) ausgewiesen, und die einzelnen berichtspflichtigen Personen von Farallon werden zusammen mit 9.157.000 Aktien (8,4%) angegeben. Mehrere zugrundeliegende Farallon-Fonds melden einzelne Bestände, darunter Farallon Capital Offshore Investors II mit 3.754.671 Aktien (3,5%) und Farallon Capital Institutional Partners mit 2.023.027 Aktien (1,9%).

Die Einreichung gibt an, dass die Aktien unmittelbar von den genannten Fonds gehalten werden und dass die General-Partner-Einheiten sowie die aufgeführten Personen als wirtschaftliche Eigentümer angesehen werden könnten, obwohl sie die wirtschaftliche Eigentümerschaft dieser Aktien zurückweisen. Das Schedule ist eine passive Offenlegung der Beteiligung und enthält eine Bestätigung, dass die Wertpapiere nicht zum Zweck einer Kontrolländerung erworben wurden.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/13/2025
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/13/2025
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025

FAQ

Who filed the Schedule 13G/A for Tango Therapeutics (TNGX)?

The filing was submitted by multiple Farallon-affiliated entities and individuals, collectively described as the "Reporting Persons," including Farallon Funds, Farallon Partners, L.L.C., and named Farallon individual reporting persons.

How many Tango Therapeutics shares do Farallon entities report owning?

Key reported amounts include Farallon Partners, L.L.C.: 8,798,334 shares (8.1%) and the Farallon Individual Reporting Persons aggregate: 9,157,000 shares (8.4%).

Are the Farallon filers reporting sole voting or dispositive power over TNGX shares?

No. The cover page rows indicate 0 sole voting power and 0 sole dispositive power for the reporting persons; the holdings are reported as shared voting and dispositive power.

Did the filers state an intent to change control of Tango Therapeutics (TNGX)?

No. The filing includes a certification stating the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Which individual Farallon reporting persons are named in the filing?

The filing names 17 individuals associated with Farallon General Partner roles, including Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, and others.

Does the filing clarify whether the Reporting Persons form a group?

The Reporting Persons state they are filing pursuant to the passive Schedule 13G provision and explicitly say they "neither disclaim nor affirm the existence of a group" among them.
Tango Therapeutics Inc

NASDAQ:TNGX

TNGX Rankings

TNGX Latest News

TNGX Latest SEC Filings

TNGX Stock Data

765.47M
104.05M
12.59%
98%
19.86%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON